Title: Impact of gplife advance diabetic support tablet as adjuvant therapy in diabetes mellitus

Biography:

Dr. Shridhar J Pandya (Doctor of Philosophy - Pharmaceutical Technology) Managing Director- Gplife Healthcare Pvt Ltd. He got his PhD from JNU & M Pharm from Pune University with Pharmaceutics as a specialization. He has 14 years experience in Pharmaceutical and Nutraceutical research field. He was Professor, Guide of Master’s and Doctorate research scholar. He published more than 25 national and international papers in reputed journals. He invented more than 50 Nutraceutical and dietary supplement formula of various diseases and many researches are going on. He developed formula with Nutropathy as an alternative option of people with diabetes & for dosage; he designed Excipients & Pharmaceutical technology for miraculous output. He is familiar with design expert, SAS software. He was chair person & Speaker of Singapore international conference of Diabetes with received best scientist award for his research. His lecture as a speaker was published in reputed journals in London, USA, Thailand, China and Singapore. He received young scientist award with best brand invention sponsored by ABP news. He is international speaker of various Pharmaceutical and Nutraceutical conferences. He is author of number of pharmaceutical research, Patent & international books. His research articles are also selected as a reference in US Patent also. He is inventor of alternative, Result oriented & safe option of various diseases like Diabetes, Obesity, Cholesterol, Triglycerides, Colon disease, Kidney, 

Abstract

Diabetes mellitus(DM) is rising in India with more than 62 million diabetic individuals. India (31.7 million) topped world with highest number of people with DM followed by US. Prevalence of DM is predicted to double globally from 171 in 2000 to 366 million in 2030. significantly effective in dropping levels of fasting plasma glucose (FPG) & post meal plasma glucose (PMG)  from baseline till day 30 as well as 60 days.  Gplife Advanced Diabetic Support Tablet was suggestively effective in dropping levels of % HbA1C from baseline to day 60 i.e. end of study. It also significantly effective in increasing levels of C- peptide levels from baseline to day 60 i.e. end of study. C- Peptide is co-secreted with insulin form pancreas and could be used as a tool in diagnosis of DM. When compared to C peptide levels in overall patients there was improvement in c- peptide levels after treatment of Gplife Advanced Diabetic Support Tablet to DM patients. It increases in the HOMA-B score and there was significant decrease in the HOMA-IR score in DM patients. It was concluded that “Gplife Advanced Diabetic Support Tablet” used as an adjuvant to OHA and insulin and helps in reducing fasting and post meal blood glucose level along with HbA1c. This can reduce the probable side effects of external insulin and OHA to subjects by providing result oriented and safer alternatives in management of DM.